Transcutaneous permeation enhancer complex for polymer-based transdermal patches
Selecting a permeation enhancer complex (PEC) for inclusion in a matrix-type transdermal patch (TP) is a primary task in creating a new dosage form with percutaneous administration. Objective: to develop a biologically safe PEC capable of regulating percutaneous diffusion of low-molecular-weight dru...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov
2025-03-01
|
| Series: | Вестник трансплантологии и искусственных органов |
| Subjects: | |
| Online Access: | https://journal.transpl.ru/vtio/article/view/1871 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849242254169866240 |
|---|---|
| author | E. G. Kuznetsova L. A. Salomatina O. M. Kuryleva Yu. B. Basok V. I. Sevastianov |
| author_facet | E. G. Kuznetsova L. A. Salomatina O. M. Kuryleva Yu. B. Basok V. I. Sevastianov |
| author_sort | E. G. Kuznetsova |
| collection | DOAJ |
| description | Selecting a permeation enhancer complex (PEC) for inclusion in a matrix-type transdermal patch (TP) is a primary task in creating a new dosage form with percutaneous administration. Objective: to develop a biologically safe PEC capable of regulating percutaneous diffusion of low-molecular-weight drugs from the polyacrylate matrix of a TP and without causing adverse skin reactions. Materials and methods. The PEC contained apricot kernel oil, dioctyl sodium sulfosuccinate, dihydroquercetin and alpha-tocopherol acetate – substances that have a good impact on the functional properties of polymer-based TPs. Low-molecular alcohol-soluble drugs (chlorpropamide, caffeine and sodium benzoate and lidocaine hydrochloride) used to treat diseases of various etiologies were used as active ingredients. In vitro studies of percutaneous drug delivery were carried out on male Chinchilla rabbits in Franz glass diffusion cells using a drug diffusion analyzer. Using spectrophotometry and high-performance liquid chromatography, concentrations of drugs in aqueous solutions and in the blood plasma of the laboratory animals were measured. The irritant effect of the lidocaine-loaded transdermal polymeric matrix was tested on sexually mature young male New Zealand White rabbits. Results. When PEC was introduced into the polymer matrix film, percutaneous diffusion of the drugs increased significantly from 2.1 ± 0.4 to 9.2 ± 1.4 mg over 24 hours of experiment for the chlorpropamide-loaded TP and from 9.2 ± 1.2 to 35.2 ± 7.5 mg for the caffeine-loaded TP. Additionally, there was a 1.7- and 2.9-fold decrease and a 2.3- and 2.7-fold increase in the time to reach a constant drug concentration in blood for the chlorpropamide- and caffeine-containing TPs, respectively. Using the lidocaine- and chlorpropamide-loaded TPs, it was shown that the presence of PEC in the polymer matrix film causes no skin irritation and that the shelf life of the transdermal form increases from 1 to 3 years. Conclusion. Introduction of the proposed PEC into the polymeric matrixes of TPs enhanced percutaneous diffusion of the drugs, reduced skin irritation from the TP components, and increased the shelf life of the finished dosage forms. |
| format | Article |
| id | doaj-art-00dc143937d346499ffd334fad81d716 |
| institution | Kabale University |
| issn | 1995-1191 |
| language | Russian |
| publishDate | 2025-03-01 |
| publisher | Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov |
| record_format | Article |
| series | Вестник трансплантологии и искусственных органов |
| spelling | doaj-art-00dc143937d346499ffd334fad81d7162025-08-20T03:59:53ZrusFederal Research Center of Transplantology and Artificial Organs named after V.I.ShumakovВестник трансплантологии и искусственных органов1995-11912025-03-0127118819710.15825/1995-1191-2025-1-188-1971326Transcutaneous permeation enhancer complex for polymer-based transdermal patchesE. G. Kuznetsova0L. A. Salomatina1O. M. Kuryleva2Yu. B. Basok3V. I. Sevastianov4Shumakov National Medical Research Center of Transplantology and Artificial OrgansShumakov National Medical Research Center of Transplantology and Artificial OrgansShumakov National Medical Research Center of Transplantology and Artificial OrgansShumakov National Medical Research Center of Transplantology and Artificial OrgansShumakov National Medical Research Center of Transplantology and Artificial Organs ; Institute of Biomedical Research and TechnologySelecting a permeation enhancer complex (PEC) for inclusion in a matrix-type transdermal patch (TP) is a primary task in creating a new dosage form with percutaneous administration. Objective: to develop a biologically safe PEC capable of regulating percutaneous diffusion of low-molecular-weight drugs from the polyacrylate matrix of a TP and without causing adverse skin reactions. Materials and methods. The PEC contained apricot kernel oil, dioctyl sodium sulfosuccinate, dihydroquercetin and alpha-tocopherol acetate – substances that have a good impact on the functional properties of polymer-based TPs. Low-molecular alcohol-soluble drugs (chlorpropamide, caffeine and sodium benzoate and lidocaine hydrochloride) used to treat diseases of various etiologies were used as active ingredients. In vitro studies of percutaneous drug delivery were carried out on male Chinchilla rabbits in Franz glass diffusion cells using a drug diffusion analyzer. Using spectrophotometry and high-performance liquid chromatography, concentrations of drugs in aqueous solutions and in the blood plasma of the laboratory animals were measured. The irritant effect of the lidocaine-loaded transdermal polymeric matrix was tested on sexually mature young male New Zealand White rabbits. Results. When PEC was introduced into the polymer matrix film, percutaneous diffusion of the drugs increased significantly from 2.1 ± 0.4 to 9.2 ± 1.4 mg over 24 hours of experiment for the chlorpropamide-loaded TP and from 9.2 ± 1.2 to 35.2 ± 7.5 mg for the caffeine-loaded TP. Additionally, there was a 1.7- and 2.9-fold decrease and a 2.3- and 2.7-fold increase in the time to reach a constant drug concentration in blood for the chlorpropamide- and caffeine-containing TPs, respectively. Using the lidocaine- and chlorpropamide-loaded TPs, it was shown that the presence of PEC in the polymer matrix film causes no skin irritation and that the shelf life of the transdermal form increases from 1 to 3 years. Conclusion. Introduction of the proposed PEC into the polymeric matrixes of TPs enhanced percutaneous diffusion of the drugs, reduced skin irritation from the TP components, and increased the shelf life of the finished dosage forms.https://journal.transpl.ru/vtio/article/view/1871transdermal patchespolymer matrix filmtranscutaneous permeation enhancerschlorpropamidecaffeine and sodium benzoatelidocaine hydrochloride |
| spellingShingle | E. G. Kuznetsova L. A. Salomatina O. M. Kuryleva Yu. B. Basok V. I. Sevastianov Transcutaneous permeation enhancer complex for polymer-based transdermal patches Вестник трансплантологии и искусственных органов transdermal patches polymer matrix film transcutaneous permeation enhancers chlorpropamide caffeine and sodium benzoate lidocaine hydrochloride |
| title | Transcutaneous permeation enhancer complex for polymer-based transdermal patches |
| title_full | Transcutaneous permeation enhancer complex for polymer-based transdermal patches |
| title_fullStr | Transcutaneous permeation enhancer complex for polymer-based transdermal patches |
| title_full_unstemmed | Transcutaneous permeation enhancer complex for polymer-based transdermal patches |
| title_short | Transcutaneous permeation enhancer complex for polymer-based transdermal patches |
| title_sort | transcutaneous permeation enhancer complex for polymer based transdermal patches |
| topic | transdermal patches polymer matrix film transcutaneous permeation enhancers chlorpropamide caffeine and sodium benzoate lidocaine hydrochloride |
| url | https://journal.transpl.ru/vtio/article/view/1871 |
| work_keys_str_mv | AT egkuznetsova transcutaneouspermeationenhancercomplexforpolymerbasedtransdermalpatches AT lasalomatina transcutaneouspermeationenhancercomplexforpolymerbasedtransdermalpatches AT omkuryleva transcutaneouspermeationenhancercomplexforpolymerbasedtransdermalpatches AT yubbasok transcutaneouspermeationenhancercomplexforpolymerbasedtransdermalpatches AT visevastianov transcutaneouspermeationenhancercomplexforpolymerbasedtransdermalpatches |